Company: PSTV
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013256
Chunk: 43

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 43
---
 proposals or nominations at the 2025 Annual Meeting of Stockholders that do not meet the additional requirements set forth in our Bylaws.

Further, even if a stockholder’s proposal is included in our proxy materials for the 2025 Annual Meeting of Stockholders, if such stockholder does not also comply with the requirements of Rule 14a-4(c)(2) under the Exchange Act, we may exercise discretionary voting authority under proxies that we solicit to vote in accordance with our best judgement on any such stockholder proposal or nomination.

#### Other Matters
We know of no other matters to be submitted at the Special Meeting of stockholders. If any other matters properly come before the Special Meeting of stockholders, it is the intention of the proxy holders to vote the shares they represent as the Board may recommend.

### WHERE YOU CAN FIND MORE INFORMATION
This proxy statement under Section 14(a) of the Exchange Act contains a notice of meeting with respect to the Special Meeting at which the Company’s stockholders will consider and vote upon the proposals described herein.

<div align='center'>25</div>

TABLE OF CONTENTS

The Company files reports, proxy statements and other information with the SEC as required by the Exchange Act. You can find the Company’s electronically filed reports, proxy, information statements and additional business and financial information about the Company included in documents previously filed by the Company with the SEC on the SEC’s website without charge at http://www.sec.gov or on the Company’s website at https:// https://plustherapeutics.com/. Information included on the Company’s website is not a part of this proxy statement. You should rely only on the information contained in this proxy statement. The Company has not authorized anyone else to provide you with any information.

| By Order of the Board                 |
| /s/ Marc H. Hedrick                   |
| MARC H. HEDRICK                       |
| President and Chief Executive Officer |
| April 10, 2025                        |

26

#### TABLE OF CONTENTS

#### Annex A

### CERTIFICATE OF AMENDMENT

### OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

#### OF

#### PLUS THERAPEUTICS, INC.
Plus Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify:

FIRST: The name of the corporation is Plus Therapeutics, Inc. (the “

#### Corporation
”).

SECOND: On [ ], [ ], the Board of Directors